MX2019003257A - Formulacion estable para la administracion parenteral de tapentadol. - Google Patents
Formulacion estable para la administracion parenteral de tapentadol.Info
- Publication number
- MX2019003257A MX2019003257A MX2019003257A MX2019003257A MX2019003257A MX 2019003257 A MX2019003257 A MX 2019003257A MX 2019003257 A MX2019003257 A MX 2019003257A MX 2019003257 A MX2019003257 A MX 2019003257A MX 2019003257 A MX2019003257 A MX 2019003257A
- Authority
- MX
- Mexico
- Prior art keywords
- tapentadol
- parenteral administration
- composition
- stable formulation
- relates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Abstract
La invención se refiere a una composición farmacéutica acuosa para la administración parenteral que comprende Tapentadol o una sal fisiológicamente aceptable de este; caracterizada porque la concentración de Tapentadol es mayor que 8.00 mg/mL, en función del peso de la base libre de Tapentadol y en función del volumen total de la composición; donde la composición comprende un sistema amortiguador y donde el valor de pH de la composición se encuentra en el intervalo de mayor que 3.0 a menor que 6.7. La invención también se refiere a un kit que comprende la composición de conformidad con la invención en un embalaje. La composición farmacéutica de conformidad con la invención es particularmente útil para tratar el dolor, especialmente el dolor agudo, preferentemente en pacientes adultos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16190255 | 2016-09-23 | ||
PCT/EP2017/073983 WO2018055070A1 (en) | 2016-09-23 | 2017-09-22 | Stable formulation for parenteral administration of tapentadol |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019003257A true MX2019003257A (es) | 2019-06-10 |
Family
ID=56997349
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019003257A MX2019003257A (es) | 2016-09-23 | 2017-09-22 | Formulacion estable para la administracion parenteral de tapentadol. |
Country Status (16)
Country | Link |
---|---|
US (1) | US10898452B2 (es) |
EP (1) | EP3515412A1 (es) |
JP (1) | JP7160799B2 (es) |
KR (1) | KR20190057349A (es) |
CN (1) | CN109996533A (es) |
AU (1) | AU2017329964B2 (es) |
BR (1) | BR112019005439A2 (es) |
CA (1) | CA3037810A1 (es) |
CL (1) | CL2019000690A1 (es) |
CO (1) | CO2019002557A2 (es) |
EA (1) | EA201990744A1 (es) |
EC (1) | ECSP19019253A (es) |
IL (1) | IL265477A (es) |
MX (1) | MX2019003257A (es) |
PE (1) | PE20190908A1 (es) |
WO (1) | WO2018055070A1 (es) |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8334422D0 (en) | 1983-12-23 | 1984-02-01 | Sterwin Ag | Composition |
GB8334423D0 (en) | 1983-12-23 | 1984-02-01 | Sterwin Ag | Composition |
US4775678A (en) | 1984-10-01 | 1988-10-04 | Schering Corporation | Clotrimazole cream |
CA2013755C (en) | 1989-04-05 | 1993-11-30 | Simon Benita | Medicinal emulsions |
DE4426245A1 (de) | 1994-07-23 | 1996-02-22 | Gruenenthal Gmbh | 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung |
FR2751875B1 (fr) * | 1996-08-05 | 1998-12-24 | Scr Newpharm | Nouvelles formulations liquides stables a base de paracetamol et leur mode de preparation |
US6183758B1 (en) | 1998-01-29 | 2001-02-06 | Highland Laboratories, Inc. | Phytochemicals, nutrients & medication absorption &/or treatment |
US6211169B1 (en) | 1999-09-29 | 2001-04-03 | Aesgen, Inc. | Stable calcitriol solution for packaging into vials |
FR2809619B1 (fr) | 2000-06-06 | 2004-09-24 | Pharmatop | Nouvelles formulations aqueuses de principes actifs sensibles a l'oxydation et leur procede d'obtention |
US6399087B1 (en) | 2000-12-20 | 2002-06-04 | Amphastar Pharmaceuticals, Inc. | Propofol formulation with enhanced microbial inhibition |
US20050176790A1 (en) | 2001-02-28 | 2005-08-11 | Johannes Bartholomaus | Pharmaceutical salts |
DE10109763A1 (de) | 2001-02-28 | 2002-09-05 | Gruenenthal Gmbh | Pharmazeutische Salze |
DE10112325A1 (de) | 2001-03-13 | 2002-10-02 | Fresenius Kabi De Gmbh | Lagerstabile Fertiginfusionslösungen des Paracetamols |
JP4905616B2 (ja) | 2001-04-19 | 2012-03-28 | ライオン株式会社 | ソフトコンタクトレンズ用点眼剤 |
US6638981B2 (en) | 2001-08-17 | 2003-10-28 | Epicept Corporation | Topical compositions and methods for treating pain |
PE20030527A1 (es) | 2001-10-24 | 2003-07-26 | Gruenenthal Chemie | Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen |
FR2832063B1 (fr) | 2001-11-15 | 2004-08-27 | Aguettant Lab | Procede de production de solutions stables de substances phenoliques et les solutions en resultant |
WO2003077897A1 (en) | 2002-03-15 | 2003-09-25 | Cypress Bioscience, Inc. | Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes |
US20030191187A1 (en) | 2002-04-01 | 2003-10-09 | Lee Fang Yu | Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same |
US20040101563A1 (en) | 2002-07-18 | 2004-05-27 | Kundu Subhas C. | Storage stable antihistaminic syrup formulations |
AU2003275329B2 (en) | 2002-09-13 | 2008-04-03 | Cydex Pharmaceuticals, Inc. | Capsules containing aqueous fill compositions stabilized with derivatized cyclodextrin |
US6888993B2 (en) | 2002-11-27 | 2005-05-03 | Corning Incorporated | Dispersion compensating optical fiber for SMF and transmission link including same |
ITMI20022748A1 (it) | 2002-12-23 | 2004-06-24 | Eurand Int | Dispersioni solide stabilizzate di farmaco in un carrier organico e procedimento per la loro preparazione. |
DK1599222T3 (da) | 2003-01-08 | 2009-04-27 | Novartis Vaccines & Diagnostic | Stabiliserede vandige pr parater omfattende v vsfaktorvej-inhibitor (TFPI) eller v vsfaktorvej-inhibitorvariant |
US20040180915A1 (en) | 2003-03-14 | 2004-09-16 | Xanodyne Pharmacal, Inc. | Methadone-containing compositions for parenteral administration and method of use thereof |
JP2007538091A (ja) | 2004-05-17 | 2007-12-27 | ファーマコフォア・インコーポレイテッド | 痛みを処置または予防するための組成物および方法 |
EP1612203B1 (en) | 2004-06-28 | 2007-08-01 | Grünenthal GmbH | Crystalline forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride |
DE102004032103A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
EP1786403B1 (de) | 2004-07-01 | 2013-07-24 | Grünenthal GmbH | Gegen missbrauch gesicherte, orale darreichungsform enthaltend (1r, 2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol |
CN101208081A (zh) | 2005-04-28 | 2008-06-25 | 谢拉奎斯特生物科学有限公司 | 治疗疼痛的方法和组合物 |
TWI329334B (en) | 2005-12-02 | 2010-08-21 | Chung Shan Inst Of Science | Manufacture method of electromagnetic interference layer for the plasma display panel |
WO2007127158A2 (en) | 2006-04-25 | 2007-11-08 | Croda, Inc | Modification of percutaneous absorption of topically active materials |
AU2007247480B8 (en) | 2006-04-28 | 2013-04-11 | Grunenthal Gmbh | Pharmaceutical combination comprising 3- (3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol and an NSAID |
PL2012764T3 (pl) | 2006-04-28 | 2011-04-29 | Gruenenthal Gmbh | Kombinacja farmaceutyczna zawierająca 3-(3-dimetyloamino-1-etylo-2-metylopropylo)fenol i Paracetamol |
DE602007004494D1 (de) | 2006-07-24 | 2010-03-11 | Janssen Pharmaceutica Nv | Herstellung von (2r,3r)-3-(3-methoxyphenyl)-n,n,2- trimethylpentanamin |
EP1905440A1 (de) | 2006-09-06 | 2008-04-02 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verwendung einer pharmazeutischen Zusammensetzung enthaltend ein Anticholinergikum zur Abtötung von Mikroorganismen und zur Behandlung von Atemwegsinfektionen |
TWI394564B (zh) | 2006-09-21 | 2013-05-01 | Alcon Res Ltd | 自行保存型水性藥學組成物 |
DE102007012165A1 (de) | 2007-03-12 | 2008-09-18 | Grünenthal GmbH | Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes |
JP2008266168A (ja) | 2007-04-18 | 2008-11-06 | Teika Seiyaku Kk | 眼科用剤 |
EP1985292A1 (en) | 2007-04-23 | 2008-10-29 | Grünenthal GmbH | Titration of tapentadol |
EP1992334A1 (en) | 2007-05-08 | 2008-11-19 | Docpharma NV/SA | Storage-stable formulation of oxidation-sensitive phenolic drug, especially paracetamol, comprises aqueous drug solution deoxygenated by a temperature-controlled manufacturing process of the formulation |
KR101972299B1 (ko) | 2007-11-23 | 2019-08-16 | 그뤼넨탈 게엠베하 | 타펜타돌 조성물 |
JP2011506342A (ja) | 2007-12-06 | 2011-03-03 | ペイン セラピューティクス インコーポレイテッド | 微粉化オピオイド組成物、製剤および剤形、ならびにそれらの製造方法 |
AU2009207796B2 (en) | 2008-01-25 | 2014-03-27 | Grunenthal Gmbh | Pharmaceutical dosage form |
BRPI0822580A2 (pt) | 2008-04-08 | 2015-06-23 | Acino Pharma Ag | Composto, recipiente, processo para produzir uma composição, uso de uma composição, e, método para controle ou prevenção de doenças infecciosas. |
BRPI0921725A2 (pt) | 2008-10-30 | 2016-01-05 | Grüenthal GmbH | formas de dosagem potentes do tapentadol |
SG172833A1 (en) | 2009-01-09 | 2011-08-29 | Panacea Biotec Ltd | Dual release pharmaceutical suspension |
US20100227921A1 (en) | 2009-03-03 | 2010-09-09 | Shire Llc | Amino acid and peptide carbamate prodrugs of tapentadol and uses thereof |
EP2246044A1 (en) | 2009-04-21 | 2010-11-03 | Pierre Fabre Dermo-Cosmétique | Paediatric solutions comprising a beta-blocker |
US20100272815A1 (en) | 2009-04-28 | 2010-10-28 | Actavis Group Ptc Ehf | Amorphous form of tapentadol hydrochloride |
JP5615821B2 (ja) | 2009-08-05 | 2014-10-29 | ナガセ医薬品株式会社 | インジゴカルミン製剤 |
US20120245230A1 (en) | 2009-12-10 | 2012-09-27 | Tecnimede-Sociedade Tecnico- Medicinal, S.A. | Method and composition for preparing stable liquid formulations of paracetamol |
US20110190267A1 (en) | 2010-01-05 | 2011-08-04 | Shire Pharmaceuticals, Inc. | Prodrugs of opioids and uses thereof |
RU2553350C2 (ru) | 2010-03-30 | 2015-06-10 | Фосфейдженикс Лимитед | Трансдермальные пластыри |
GB201006200D0 (en) | 2010-04-14 | 2010-06-02 | Ayanda As | Composition |
US20120270848A1 (en) | 2010-10-22 | 2012-10-25 | Galleon Pharmaceuticals, Inc. | Novel Compositions and Therapeutic Methods Using Same |
US9446008B2 (en) | 2011-03-04 | 2016-09-20 | Gruenenthal Gmbh | Semisolid aqueous pharmaceutical composition containing tapentadol |
RS59491B1 (sr) * | 2011-03-04 | 2019-12-31 | Gruenenthal Gmbh | Vodena farmaceutska formulacija tapentadola za oralnu primenu |
CN107088226A (zh) | 2011-03-04 | 2017-08-25 | 格吕伦塔尔有限公司 | 他喷他多的胃肠外给药 |
US20150073000A1 (en) | 2012-03-27 | 2015-03-12 | Fresenius Kabi Oncology Limited | Stable ready-to-use pharmaceutical composition of pemetrexed |
CN103159633B (zh) | 2012-07-06 | 2015-08-12 | 江苏恩华药业股份有限公司 | 他喷他多的制备方法及用于制备他喷他多的化合物 |
US9629818B2 (en) * | 2012-11-01 | 2017-04-25 | Torrent Pharmaceuticals Ltd. | Pharmaceutical composition of tapentadol for parenteral administration |
US9072781B2 (en) * | 2013-03-14 | 2015-07-07 | Becton, Dickinson France S.A.S. | Morphine formulations |
GB201309654D0 (en) | 2013-05-30 | 2013-07-17 | Euro Celtique Sa | Method |
CN103735550B (zh) | 2013-12-25 | 2015-11-18 | 上海市闸北区中心医院 | 一种治疗慢性肾脏病心肌损伤的药物组合物及其应用 |
CN103735500B (zh) | 2014-01-28 | 2016-01-20 | 江苏华泽医药科技有限公司 | 盐酸他喷他多注射液及其制备方法 |
JP6923447B2 (ja) | 2015-03-27 | 2021-08-18 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | タペンタドールの非経口投与のための安定な製剤 |
WO2018153947A1 (en) * | 2017-02-23 | 2018-08-30 | Grünenthal GmbH | Tapentadol as local anesthetic |
-
2017
- 2017-09-22 AU AU2017329964A patent/AU2017329964B2/en active Active
- 2017-09-22 JP JP2019515433A patent/JP7160799B2/ja active Active
- 2017-09-22 BR BR112019005439A patent/BR112019005439A2/pt not_active Application Discontinuation
- 2017-09-22 CA CA3037810A patent/CA3037810A1/en not_active Abandoned
- 2017-09-22 EA EA201990744A patent/EA201990744A1/ru unknown
- 2017-09-22 US US15/712,812 patent/US10898452B2/en active Active
- 2017-09-22 PE PE2019000676A patent/PE20190908A1/es unknown
- 2017-09-22 WO PCT/EP2017/073983 patent/WO2018055070A1/en active Search and Examination
- 2017-09-22 EP EP17777835.4A patent/EP3515412A1/en active Pending
- 2017-09-22 KR KR1020197011410A patent/KR20190057349A/ko not_active Application Discontinuation
- 2017-09-22 CN CN201780058585.4A patent/CN109996533A/zh active Pending
- 2017-09-22 MX MX2019003257A patent/MX2019003257A/es unknown
-
2019
- 2019-03-18 CL CL2019000690A patent/CL2019000690A1/es unknown
- 2019-03-19 IL IL265477A patent/IL265477A/en unknown
- 2019-03-19 EC ECSENADI201919253A patent/ECSP19019253A/es unknown
- 2019-03-19 CO CONC2019/0002557A patent/CO2019002557A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2017329964A1 (en) | 2019-03-14 |
US10898452B2 (en) | 2021-01-26 |
EP3515412A1 (en) | 2019-07-31 |
US20180085328A1 (en) | 2018-03-29 |
BR112019005439A2 (pt) | 2019-06-18 |
WO2018055070A1 (en) | 2018-03-29 |
KR20190057349A (ko) | 2019-05-28 |
JP7160799B2 (ja) | 2022-10-25 |
AU2017329964B2 (en) | 2022-10-06 |
CO2019002557A2 (es) | 2019-05-10 |
JP2019529442A (ja) | 2019-10-17 |
CN109996533A (zh) | 2019-07-09 |
CL2019000690A1 (es) | 2019-06-14 |
CA3037810A1 (en) | 2018-03-29 |
PE20190908A1 (es) | 2019-06-26 |
ECSP19019253A (es) | 2019-03-29 |
IL265477A (en) | 2019-05-30 |
EA201990744A1 (ru) | 2019-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP4233892A3 (en) | Stable anti-ifnar1 formulation | |
US20200237664A1 (en) | Methotrexate Composition | |
CY1124546T1 (el) | Υγρο σκευασμα για εισπνοη που περιεχει rpl554 | |
CA3030422C (en) | Stabilizing excipients for therapeutic protein formulations | |
MX2021005012A (es) | Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de su uso como inhibidores de la cinasa atr. | |
MX2022003072A (es) | Uso de pridopidina para el tratamiento de la disminucion funcional. | |
SG10201903619YA (en) | Carbazole derivatives | |
MX2017012312A (es) | Formulacion estable para administracion parenteral de tapentadol. | |
HUP0105173A2 (hu) | Adagolási módszer és készítmény sürgősségi fogamzásgátlásra | |
NZ702342A (en) | Pharmaceutical formulation | |
JP2014237607A (ja) | ペメトレキセドを含む注射用組成物 | |
MX2015009546A (es) | Dosificacion aumentada de efavirenz para el tratamiento de cancer. | |
MX2019003257A (es) | Formulacion estable para la administracion parenteral de tapentadol. | |
ZA202200331B (en) | Naltrexone formulation | |
TW200626133A (en) | Oral medication for twice-daily administration | |
EA202090965A1 (ru) | Водные композиции биластина | |
EA202090416A1 (ru) | Способы лечения симптомов гастропареза с использованием велусетрага | |
MX2016003327A (es) | Composicion farmaceutica de citrato de sildenafilo en forma de suspension para uso oral. | |
AR104051A1 (es) | Formulación estable para administración parenteral de tapentadol | |
MX2018008443A (es) | Composición farmacéutica que comprende nebivolol con tasa de disolución mejorada. | |
ZA202301927B (en) | Phytonadione compositions | |
PH12020500001A1 (en) | Non-pulsatile prolonged-release betahistine oral solid compositions | |
ZA202104167B (en) | Compounds for use in the treatment of parkinson's disease | |
ZA202200330B (en) | Pharmaceutical composition of imatinib | |
UA123395U (uk) | Фармацевтична композиція ністатину у формі оральної суспензії |